Stay updated on Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.

Latest updates to the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page
- Check6 days agoChange DetectedThe webpage has updated its date references, replacing the previous year's dates with those for 2025.SummaryDifference0.2%
- Check13 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check35 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check63 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check78 days agoChange DetectedThe page has been updated to reflect a new version (v2.15.0) and includes the addition of 'Non-Small Cell Lung Cancer' and 'Collaborators Exelixis', while significant details about the study's purpose and inclusion/exclusion criteria have been removed.SummaryDifference44%
Stay in the know with updates to Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in NSCLC: RET, ROS1, NTRK, MET Clinical Trial page.